Compare AKBA & ALCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKBA | ALCO |
|---|---|---|
| Founded | 2007 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 297.9M |
| IPO Year | 2014 | 1994 |
| Metric | AKBA | ALCO |
|---|---|---|
| Price | $0.93 | $41.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.67 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 5.7M | 13.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 0.49% |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $39.81 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $30.95 |
| 52 Week High | $4.08 | $45.01 |
| Indicator | AKBA | ALCO |
|---|---|---|
| Relative Strength Index (RSI) | 38.26 | 51.45 |
| Support Level | $0.88 | $39.94 |
| Resistance Level | $1.56 | $42.23 |
| Average True Range (ATR) | 0.07 | 0.77 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 43.33 | 59.24 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.